CAW
NBIX icon

Cornerstone Advisors (Washington)’s Neurocrine Biosciences NBIX Stock Holding History

Cornerstone Advisors (Washington)’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-56
Closed -$5K – 1177
2019
Q2 		$5K Buy
56
+31
+124% +$2.54K ﹤0.01% 929
2019
Q1 		$2K Buy
+25
New +$2.09K ﹤0.01% 1030

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cornerstone Advisors (Washington)'s NBIX Position: Q3 2019 in Review

Cornerstone Advisors (Washington) sold out of Neurocrine Biosciences (NBIX) in Q3 2019, closing a stake of 56 shares — an estimated $5K sold.

Cornerstone Advisors (Washington) first reported a position in NBIX in Q1 2019 and held it in 2 quarters. The position peaked at $5K in Q2 2019. 332 funds tracked by Wall St. Rank hold NBIX as of Q3 2019.

  • Cornerstone Advisors (Washington) reported no remaining Neurocrine Biosciences position as of Q3 2019 after selling out during the quarter.
  • Cornerstone Advisors (Washington) sold 56 Neurocrine Biosciences shares in Q3 2019, an estimated $5K.
  • Cornerstone Advisors (Washington) first reported a position in Neurocrine Biosciences in Q1 2019 and held it in 2 quarters.
  • Cornerstone Advisors (Washington)'s Neurocrine Biosciences position peaked at $5K in Q2 2019.
  • 332 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2019.

Based on Cornerstone Advisors (Washington)'s 13F filing for Q3 2019, filed 23 Oct 2019.